Results 131 to 140 of about 755,616 (163)

Remibrutinib as a Therapeutic Option for Solar Urticaria

open access: yes
Photodermatology, Photoimmunology &Photomedicine, Volume 42, Issue 6, November 2026.
Joshua Mijares   +3 more
wiley   +1 more source

S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY

open access: yesHemaSphere, 2023
Yan Shi   +12 more
doaj   +1 more source

Delayed Cutaneous Ecchymosis with Bruton’s Tyrosine Kinase Inhibitors and Breast Radiation: A Case Report

open access: yesAdvances in Radiation Oncology
Jinah Kim, MD   +2 more
doaj   +1 more source

A Small Molecule Inhibitor of Bruton’s Tyrosine Kinase Involved in B‑Cell Signaling

open access: yesACS Omega, 2017
Einav Ratzon   +7 more
doaj   +1 more source

PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES

open access: yesHemaSphere, 2023
Kim Linton   +10 more
doaj   +1 more source

Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema

open access: yesJAAD Case Reports
Shannon Meledathu, BS   +4 more
doaj   +1 more source

Bruton’s tyrosine kinase inhibitors in diffuse large B-cell lymphoma therapy: critical considerations and future innovations

open access: yesJournal of Translational Medicine
Chuanyang Lu   +6 more
doaj   +1 more source

Correction: Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma

open access: yesJournal of Experimental & Clinical Cancer Research
Jin Wang   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy